Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function

Neuropsychopharmacology

Volumn 28, Issue 6, 2003, Pages 1106-1116

  Spielewoy, Cecile ^a,b   Markou, Athina ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Brain stimulation reward; Depression; Negative symptoms of schizophrenia; Phencyclidine; Rat; Thresholds; Withdrawal

Indexed keywords

PHENCYCLIDINE;

ANIMAL; ARTICLE; BRAIN; CHEMICALLY INDUCED DISORDER; DEPRESSION; DRUG EFFECT; MALE; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RAT; REACTION TIME; REWARD; WISTAR RAT; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; DEPRESSION; MALE; PHENCYCLIDINE; RATS; RATS, WISTAR; REACTION TIME; REWARD; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0041842701     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300124     Document Type: Article

References (89)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC.
2. Baldo BA, Koob GF, Markou A (1999). Role of adenosine a2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J Neurosci 19: 11017-11026.
3. Balla A, Koneru R, Smiley J, Sershen H, Javitt DC (2001). Continuous phencyclidine treatment induced schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology 25: 157-164.
4. Barr GA, Paredes W, Bridger WH (1985). Place conditioning with morphine and phencyclidine: dose-dependent effects. Life Sci 36: 363-368.
5. Bespalov A, Lebedev A, Panchenko G, Zvartau E (1999). Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. Eur Neuropsychopharmacol 9: 377-383.
6. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989). Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653-661.
7. Carlezon Jr WA, Wise RA (1993). Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration. Psychopharmacology 111: 402-408.
8. Carlezon Jr. WA, Wise RA (1996a). Microinjections of phencyclidine (PCP) and related drugs into nucleus accumbens shell potentiate medial forebrain bundle brain stimulation reward. Psychopharmacology 128: 413-420.
9. Carlezon Jr. WA, Wise RA (1996b). Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci 16: 3112-3122.
10. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 41: 237-260.
11. Castren E, da Penha Berzaghi M, Lindholm D, Thoenen H (1993). Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neurol 122: 244-252.
12. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR (1984). Prediction of abuse liability of drugs using intravenous selfadministration by rats. Psychopharmacology 82: 6-13.
13. Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB et al (1997). Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res 752: 1-14.
14. Crider R (1986). Phencyclidine: changing abuse patterns. NIDA Res Monograms 64: 163-173.
15. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001). Methamphe- tamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36: 1-22.
16. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
17. Ellison G (1994). Competitive and noncompetitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5: 2688-2692.
18. Ellison G, Switzer RC (1993). Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5: 17-20.
19. Engen T (1971). Psychophysics. In: Kling JW, Riggs LA (eds). Woodworth and Schlosberg’s Experimental Psychology, 3rd edn. Holt, Rinehart and Winston: New York. pp 11-46.
20. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998). Dramatic decrease in brain reward function during nicotine withdrawal. Nature 393: 76-79.
21. Fram DH, Stone N (1986). Clinical observations in the treatment of adolescent and young adult PCP abusers. NIDA Res Monograms 64: 252-261.
22. Gao XM, Hashimoto T, Tamminga CA (1998). Phencyclidine (PCP) and dizocilpine (MK-801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 29: 14-28.
23. Gerhardt GA, Pang K, Rose GM (1987). In vivo electrochemical demonstration of the presynaptic actions of phencyclidine in rat caudate nucleus. J Pharmacol Exp Ther 241: 714-721.
24. Geyer MA, Markou A (1995). Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York. pp 787-798.
25. Glick SD, Weaver LM, Meibach RC (1980). Lateralization of reward in rats: differences in reinforcing thresholds. Science 207: 1093-1095.
26. Harrison AA, Liem TB, Markou A (2001). Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25: 55-71.
27. Horger BA, Lyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR (1999). Enhancement of locomotor activity and conditioned reward cocaine by brain-derived neurotrophic factor. J Neurosci 19: 4110-4122.
28. Hughes P, Dragunow M, Beilharz E, Lawlor P, Gluckman P (1993). MK-801 induces immediate-early gene proteins and BDNF mRNA in rat cerebrocortical neurones. Neuroreport 4: 183-186.
29. Iwamoto ET (1986). Place-aversion conditioned by phencyclidine in rats: development of tolerance and pharmacological antagonism. Alcohol Drug Res 6: 265-276.
30. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301.
31. Jentsch JD, Elsworth JD, Redmond Jr DE, Roth RH (1997a). Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by isomers of HA966. J Neurosci 17: 1769-1775.
32. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997b). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953-955.
33. Jentsch JD, Roth RH (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20: 201-225.
34. Jentsch JD, Taylor JR, Roth RH (1998b). Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology 19: 105-113.
35. Jentsch JD, Tran A, Dung LE, Youngren KD, Roth RH (1997c). Subchronic phencyclidine administration reduces mesoprefron- tal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99.
36. Jentsch JD, Tran A, Taylor JR, Roth RH (1998a). Prefrontal cortical involvement in phencyclidine-induced activation of the meso- limbic dopamine system: behavioral and neurochemical evidence. Psychopharmacology 138: 89-95.
37. Johnson KM, Phillips M, Wang C, Kevetter GA (1998). Chronic phencyclidine induces behavioral sensitization and apoptotic cell death in the olfactory and piriform cortex. J Neurosci Res 52: 709-722.
38. Kitaichi K, Noda Y, Hasegawa T, Furukawa H, Nabeshima T (1996). Acute phencyclidine induces aversion, but repeated phencyclidine induces preference in the place conditioning test in rats. Eur J Pharmacol 318: 7-9.
39. Kitaichi K, Noda Y, Miyamoto Y, Numaguchi A, Osawa H, Hasegawa T et al (1999). Involvement of the serotonergic neuronal system in phencyclidine-induced place aversion in rats. Behav Brain Res 103: 105-111.
40. Kokkinidis L, Zacharko RM (1980). Enhanced lateral hypothalamic self-stimulation responding after chronic exposure to amphetamine. Behav Neural Biol 29: 493-497.
41. Kokkinidis L, Zacharko RM, Anisman H (1986). Amphetamine withdrawal: a behavioral evaluation. Life Sci 38: 1617-1623.
42. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
43. Kornetsky C, Esposito R, Mc Lean S, Jacobson JO (1979). Intracranial self-stimulation thresholds. Arch Gen Psychiatry 36: 289-292.
44. Kornetsky C, Markowitz RA, Esposito RU (1981). Phencyclidine and naloxone: effects on sensitivity to aversive and rewarding stimulation in the rat. In: Domino EF (ed). PCP (Phencyclidine): Historical and Current Perspectives. NPP books: Ann Arbor, MI. pp 321-330.
45. Kuhar MJ, Baja JW, Cone EJ (1990). Phencyclidine binding to striatal receptors. Neuropharmacology 29: 295-297.
46. Leith NJ, Barrett RJ (1976). Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacology 46: 19.
47. Lin D, Koob GF, Markou A (1999). Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-Interactions between the two drugs. Psychopharmacology 145: 283-294.
48. Lipska BK, Khaing ZZ, Weickert CS, Weinberger DR (2001). BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur J Neurosci 14: 135-144.
49. Markou A, Frank RA (1987). The effect of operant and electrode placement on self-stimulation train duration response functions. Physiol Behav 41: 303-308.
50. Markou A, Kenny JP (2002). Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories. Neurotoxicity Res 4: 297-313.
51. Markou A, Koob GF (1991). Postcocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology 4: 17-26.
52. Markou A, Koob GF (1992a). Bromocriptine reverses the elevation in intracranial self-stimulation thresholds observed in a rat model of cocaine withdrawal. Neuropsychopharmacology 7: 213-224.
53. Markou A, Koob GF (1992b). Construct validity of a selfstimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51: 111-119.
54. Markou A, Koob GF (1993). Intracranial self-stimulation threshold as a measure of reward. In: Sagal A (ed). Behavioural Neuroscience: A Practical Approach. Oxford University Press: New York. pp 93-115.
55. Markou A, Kosten TR, Koob GF (1998). Neurobiological similarities in depression and drug-dependence: a self-medication hypothesis. Neuropsychopharmacology 18: 135-174.
56. Nabeshima T, Fukaya H, Yamaguchi K, Ishikawa K, Furukawa H, Kameyama T (1987). Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur J Pharmacol 135: 23-33.
57. Nabeshima T, Kitaichi K, Noda Y (1996). Functional changes in neuronal systems induced by phencyclidine administration. Ann NY Acad Sci 801: 29-38.
58. Nabeshima T, Noda Y, Yamaguchi K, Ishikawa K, Furukawa H, Kameyama T (1985). Acute and chronic phencyclidine changes serotonin receptors in rat brain. Eur J Pharmacol 109: 129-132.
59. Nakki R, Sharp FR, Sagar SM, Honkaniemi J (1996). Effects of phencyclidine on immediate early gene expression in the brain. J Neurosci Res 45: 13-27.
60. Nestler EJ (2001). Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2: 119-128.
61. Nestler EJ, Aghajanian GK (1997). Molecular and cellular basis of addiction. Science 278: 58-63.
62. Nestler EJ, Barrot M, Di Leone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron 34: 13-25.
63. Noda Y, Kamei H, Mamiya T, Furukawa H, Nabeshima T (2000). Repeated phencyclidine treatment induces negative symptomlike behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23: 375-387.
64. Noda Y, Miyamoto Y, Takayoshi M, Kamei H, Furukawa H, Nabeshima T (1998). Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. J Pharmacol Exp Ther 286: 44-51.
65. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116: 2531-2537.
66. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiat Res 33: 523-533.
67. O’Neill MF, Hicks CA, Shaw G, Parameswaran T, Cardwell GP, O’Neill MJ (1998). Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. J Pharmacol Exp Ther 287: 839-846.
68. Paterson NE, Myers C, Markou A (2000). Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology 152: 440.
69. Pellegrino LJ, Pellegrino AS, Cushman AJ (1979). A Stereotaxic Atlas of the Rat Brain, 2nd edn. Plenum Press: New York.
70. Phillips AG, Fibiger HC (1989). Neuroanatomical bases of ICSS—untying the Gordian knot. In: Liebman JM, Cooper SJ (eds). The Neuropharmacological Basis of Reward. Oxford University Press: New York. pp 66-105.
71. Phillips M, Wang C, Johnson KM (2001). Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther 296: 905-913.
72. Pliakas AM, Carlson RR, Neve RL, Kondari C, Nestler EJ, Carlezon Jr WA (2001). Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding expression in nucleus accum- bens. J Neurosci 21: 7397-7403.
73. Quiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H et al (2001). Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12: 11-15.
74. Rothman RB, Reid AA, Monn JA, Jacobson AE, Rice KC (1989). The psychotomimetic drug phencyclidine labels two high affinity binding sites in guinea pig brain: evidence for N-methyl-D- aspartate-coupled and dopaminergic reuptake carrier-associated phencyclidine binding sites. Mol Pharmacol 36: 887-896.
75. Schaefer GJ, Michael RP (1990). Interactions of naloxone with morphine, amphetamine and phencyclidine on fixed interval responding for intracranial self-stimulation in rats. Psychopharmacology 102: 263-268.
76. Schroeder U, Schroeder H, Darius J, Grecksch G, Sabel AA (1998). Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav Brain Res 97: 59-68.
77. Schulteis G, Markou A, Cole M, Koob GF (1995). Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92: 5880-5884.
78. Schulteis G, Markou A, Gold LH, Stinus L, Koob GF (1994). Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-reponse analysis. J Pharmacol Exp Ther 271: 1391.
79. Sharp FR, Butman M, Wang S, Koistinaho J, Graham SH, Sagar SM et al (1992). Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J Neurosci Res 33: 605-616.
80. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001). Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia. Trends Neurosci 24: 330-334.
81. Siegel S (1975). Evidence from rats that morphine tolerance is a learned response. J Comp Physiol Psychol 89: 498-506.
82. Skjei KL, Markou A (2003). Effects of repeated withdrawal episodes, nicotine dose, and duration of nicotine exposure on the severity and duration of nicotine withdrawal in rats. Psychopharmacol, in press.
83. Smith RC, Meltzer HY, Arora RC, Davis JM (1977). Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26: 1435-1439.
84. Solomon RL, Corbit JD (1974). An opponent-process theory of motivation. Psychol Rev 81: 119-145.
85. Stellar JR, Rice MB (1989). Pharmacological basis of ICSS reward. In: Liebman JM, Cooper SJ (eds). The Neuropharmacological Basis of Reward. Oxford University Press: New York. pp 14-65.
86. Storvik M, Lindén A-M, Kontkanen O, Lakso M, Castren E, Wong G (2000). Induction of cAMP response element modulator (CREM) and inducible cAMP early repressor (ICER) expression in rat brain by uncompetitive N-methyl-D-aspartate receptor antagonists. J Pharmacol Exp Ther 294: 52-60.
87. Sturgeon RD, Fessler RG, London SF, Meltzer HY (1982). Behavioral effects of chronic phencyclidine administration in rats. Psychopharmacology 76: 52-56.
88. Wise RA (1989). The brain and reward. In: Liebman JM, Cooper SJ (eds). The Neuropharmacological Basis of Reward. Oxford University Press: Oxford. pp 377-424.
89. Wise RA, Bauco P, Carlezon Jr WA (1992). Self-stimulation and drug reward mechanisms. Ann NY Acad Sci 654: 192-198.